BIONTECH SE (BNTX): Price and Financial Metrics


BIONTECH SE (BNTX): $372.65

17.40 (+4.90%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BNTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 506

in industry

BNTX Stock Summary

  • BNTX's went public 1.47 years ago, making it older than just 1.29% of listed US stocks we're tracking.
  • With a price/sales ratio of 196.3, BioNTech SE has a higher such ratio than 97.53% of stocks in our set.
  • In terms of twelve month growth in earnings before interest and taxes, BioNTech SE is reporting a growth rate of 292.66%; that's higher than 94.66% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to BioNTech SE are ENTA, MORF, RCUS, NTLA, and MGNX.
  • BNTX's SEC filings can be seen here. And to visit BioNTech SE's official web site, go to www.biontech.de.

BNTX Stock Price Chart Interactive Chart >

Price chart for BNTX

BNTX Price/Volume Stats

Current price $372.65 52-week high $464.00
Prev. close $355.25 52-week low $58.81
Day low $345.00 Volume 4,602,056
Day high $374.85 Avg. volume 3,100,229
50-day MA $325.49 Dividend yield N/A
200-day MA $189.45 Market Cap 90.37B

BIONTECH SE (BNTX) Company Bio


BioNTech SE focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches. The firm develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products. It offers drug discovery services for therapeutic areas including infectious diseases, allergies and autoimmune disorders.


BNTX Latest News Stream


Event/Time News Detail
Loading, please wait...

BNTX Latest Social Stream


Loading social stream, please wait...

View Full BNTX Social Stream

Latest BNTX News From Around the Web

Below are the latest news stories about BioNTech SE that investors may wish to consider to help them evaluate BNTX as an investment opportunity.

Moderna, BioNTech Plunge As Key Officials Argue Against Covid Booster Shots

Vaccine stocks Moderna, BioNTech and Pfizer toppled Monday after a bevy of scientists argued against Covid booster shots.

Yahoo | September 13, 2021

Moderna Stock Is Tanking After a Review Arguing That Covid Vaccine Boosters Aren’t Needed

An article in the Lancet suggested that a booster shot wouldn't be necessary for most people after a review of data from clinical trials, as well as efficacy in the real world.

Yahoo | September 13, 2021

NYC has a good plan so far for keeping kids safe as they return to the classroom: Doctor

Dr. Susannah Hills, Pediatric Airway Surgeon and Assistant Professor of ENT at Columbia University Medical Center, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.

Yahoo | September 13, 2021

Will COVID-19 Vaccines for Children be Available by Year-End?

The FDA is trying to make available a safe and effective COVID-19 vaccine for use in children below 12 years of age as soon as possible.

Yahoo | September 13, 2021

Israel weighing fourth round of coronavirus vaccines: report

Israel is considering a fourth round of coronavirus vaccines, Bloomberg News reported, citing an interview a health ministry official gave to a local radio station. "We don't know when it will happen; I hope very much that it won't be within six months, like this time, and that the third dose will last for longer," Health Ministry Director General Nachman Ash said in an interview with Radio 103FM,

Yahoo | September 13, 2021

Read More 'BNTX' Stories Here

BNTX Price Returns

1-mo 1.74%
3-mo 75.43%
6-mo 246.36%
1-year 464.28%
3-year N/A
5-year N/A
YTD 357.13%
2020 140.61%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9492 seconds.